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A B S T R A C T
Purpose
The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with
early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that
a switch from adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane was
associated with clinically relevant improvements in efﬁcacy. Here, we report the ﬁnal efﬁcacy
analyses of this cohort.
Patients and Methods
Patients who remained disease free after 2 to 3 years of adjuvant tamoxifen were randomly
assigned to continue tamoxifen or switch to exemestane to complete a total of 5 years of adjuvant
endocrine therapy. Given the large number of non–breast cancer–related deaths now reported,
breast cancer–free survival (BCFS), with censorship of intercurrent deaths, was the primary survival
end point of interest. Analyses focus on patients with estrogen receptor-positive or unknown tumors
(n = 4,599).
Results
At the time of the data snapshot, median follow-up was 120 months. In the population that was
estrogen receptor positive or had unknown estrogen receptor status, 1,111 BCFS events were
observed with 508 (22.1%) of 2,294 patients in the exemestane group and 603 (26.2%) of 2,305
patients in the tamoxifen group. The data corresponded to an absolute difference (between
exemestane and tamoxifen) at 10 years of 4.0% (95%CI, 1.2% to 6.7%), and the hazard ratio (HR) of
0.81 (95% CI, 0.72 to 0.92) favored exemestane. This difference remained in multivariable analysis
that was adjusted for nodal status, prior use of hormone replacement therapy, and prior chemo-
therapy (HR, 0.80; 95% CI, 0.71 to 0.90; P , .001). A modest improvement in overall survival was
seenwith exemestane; the absolute difference (between exemestane and tamoxifen) at 10 years in
the population that was estrogen receptor positive or had unknown estrogen receptor status was
2.1% (95% CI, 20.5% to 4.6%), and the HR was 0.89 (95% CI, 0.78 to 1.01; P = .08). For the
intention-to-treat population, the absolute difference was 1.6% (95% CI, 20.9% to 4.1%); the HR
was 0.91 (95% CI, 0.80 to 1.03, P = .15). No statistically signiﬁcant difference was observed in the
proportion of patients who reported a fracture event in the post-treatment period.
Conclusion
The Intergroup Exemestane Study and contemporaneous studies have established that a strategy of
switching to an aromatase inhibitor after 2 to 3 years of tamoxifen can lead to sustained beneﬁts in
terms of reduction of disease recurrence and breast cancer mortality.
J Clin Oncol 35:2507-2514. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Despite improvements in adjuvant treatment,
breast cancer remains the most frequent cause of
cancer-related death in women; approximately
508,000 deaths were reported worldwide in 2011.1
For patients diagnosed with estrogen receptor
(ER)–positive disease, risk of disease relapse re-
mains for more than 15 years after initial di-
agnosis; and recent research has demonstrated
that patients who received chemotherapy had
a cumulative risk of relapse at 15 years compa-
rable to that of patients with ER-negative disease.2
Aromatase inhibitors reduce recurrence rates and
10-year breast cancer mortality rates compared
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with tamoxifen. However, the optimal way to schedule aromatase
inhibitors is still debated.3
The Intergroup Exemestane Study (IES) was an investigator-
led, Pﬁzer-sponsored trial to assess the affect on disease-related
outcome, adverse events, and quality of life of a switch to exemestane
after 2 to 3 years of tamoxifen compared with continuation up to 5
years of tamoxifen.4-11 The most recent update of efﬁcacy analyses
published in 2012 (data snapshot on December 7, 2009) after a
median follow-up of 91 months demonstrated that the highly sta-
tistically signiﬁcant beneﬁt of a switch to exemestane on disease-free
survival (DFS) observed at initial publicationwasmaintained, and this
translated to a modest improvement in overall survival (OS).6
IES was the ﬁrst trial published to describe the beneﬁts of
a switch from tamoxifen to an aromatase inhibitor (exemestane) at
2 to 3 years, and it was one of the pivotal trials to assess the role of
aromatase inhibitors in combination with or as a replacement for
standard tamoxifen treatment.3 Whether the strategy results in
long-term sustained improvement in DFS or OS remains con-
troversial, although our previous report suggested that this was the
case.6
Recent analyses of the Arimidex, Tamoxifen, Alone or in
Combination (ATAC) trial have sought to identify clinical and
biologic factors associated with disease relapse after completion of
endocrine therapy.12,13 Nodal involvement and tumor size are the
most important clinical factors for prediction of relapse both
during and after treatment completion in patients with ER-positive
breast cancer.14,15 The other aim of this study, therefore, was to
establish which prognostic features were important in the IES trial,
which used a switching strategy, especially after the end of en-
docrine therapy.
Here, we present the ﬁnal efﬁcacy analysis of the IES, along
with exploratory analyses to investigate clinical factors that affect
the risk of distant relapse after completion of endocrine therapy.
PATIENTS AND METHODS
Patients
Details of trial design, eligibility criteria, and study procedures
have been presented previously.4-6 Brieﬂy, eligible patients were post-
menopausal women with ER-positive/unknown primary invasive breast
cancer who remained disease free and on treatment after 2 to 3 years of
tamoxifen. At random assignment, women were allocated to continue
tamoxifen (20mg [or 30mg in Denmark] daily) or to switch to exemestane
(25 mg daily) for the remainder of the 5-year endocrine therapy period.
Timing of analyses was preplanned and triggered according to the last
patient randomly assigned to reach her 10-year follow up. This analysis
includes all data received as of September 4, 2013.
Efﬁcacy analyses presented here were performed on the main IES
analysis population, which included patients whose tumors were ER
positive (n = 4,052; 85.8%) plus those whose ER status was unknown (n =
547; 11.6%). Analyses excluded patients who had ER-negative disease (n =
125; 2.6%) who would not have been eligible for the trial had their receptor
statuses been known at trial entry. Intention-to-treat (ITT) analysis of
overall survival is included for completeness.
Statistical Analysis
The primary end point of the IES was DFS, deﬁned as time from
random assignment to local or distant breast cancer recurrence, new
primary breast cancer, or death without disease relapse (intercurrent
death). As reported previously,6 the proportion of patients who experi-
enced intercurrent death increased as the IES population aged, which
decreased the sensitivity of DFS to detect differences between treatments in
breast cancer outcome. Therefore, breast cancer–free survival (BCFS), in
which intercurrent deaths are censored, is now regarded as a more direct
estimate of the treatment effect on breast cancer outcome in the long term.
Other secondary end points presented include OS (deﬁned as time from
random assignment to death as a result of any cause), breast cancer–
speciﬁc survival (BCSS; deﬁned as time from random assignment to breast
cancer death, including death as a result of unknown cause and other cause
after recurrence), time to contralateral breast cancer (CLB; deﬁned as time
to contralateral breast cancer with patients censored at time of nonbreast
second primary cancer), and time to distant recurrence (TTDR; deﬁned as
time to distant recurrence or death as a result of breast cancer or unknown
cause without prior recurrence).
Kaplan-Meier plots, log-rank tests, and Cox proportional hazards
analyses were used to compare survival end points between randomly
assigned treatment groups. Multivariable analysis that was adjusted for
known prognostic factors of nodal status, chemotherapy use, and hormone
replacement therapy (HRT) use also was conducted.
Sites of ﬁrst distant recurrence were grouped as either visceral, bone,
or soft tissue/nodal. Patients were assigned to multiple groups, when
relevant. Progression of metastatic disease subsequent to the initial distant
recurrence was ignored. Events in which the site of recurrence was un-
known were excluded from this part of the analysis.
The overall and age-related incidences of non–breast cancer second
primary cancers were investigated to conﬁrm the observation in pre-
vious reports of a differential pattern according to randomly assigned
treatment.5,6 When patients reported more than one nonbreast second primary
cancer (n = 6), the ﬁrst reported event was included. Second primaries
reported with no conﬁrmed date of diagnosis were excluded (n = 8).
Competing-risks analyses were undertaken to assess the impact of the
randomly assigned treatment on breast cancer events (local recurrence,
distant recurrence, CLB, ipsilateral breast cancer, and death as a result of
breast cancer or an unknown cause) allowing for competing risks of in-
tercurrent death and nonbreast second primary cancer. Patients were
included on the basis of which event occurred ﬁrst: breast cancer event or
competing risk event. Gray’s test was used to compare the two treatment
groups with respect to breast cancer event in the presence of competing
risks.16
Landmark analyses were performed to investigate the factors re-
lated to distant recurrence after the end of endocrine therapy. TTDR was
the end point of interest, and survival time was partitioned at 2.5 years,
which represented the approximate end of endocrine therapy in IES. The
effect of randomly assigned treatment and of a number of patient and
tumor characteristics on TTDR after 2.5 years were assessed, both as
single variables and together in a multivariable Cox proportional hazards
model.
Full adverse event4-7,11 and quality of life9,10 data have been reported
previously and, therefore, are not included in this article, but an updated
estimate of post-treatment fracture incidence by treatment received is
presented. This estimate includes all fractures that occurred. 6 months
after treatment completion in patients who received at least 1 day of
treatment, and events were censored after recurrence or new second
primary cancer.
Analyses were performed with STATA, version 13.2 (STATA Corp,
College Station, TX). All statistical tests were two sided, and P , .05 was
considered statistically signiﬁcant.
RESULTS
Between 1998 and 2003, 4,724 evaluable patients were randomly
assigned from 366 sites in 37 countries. Of these, 4,599 patients
were ER positive or had an unknown ER status (Fig 1).
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Patient characteristics have been reported previously; patients
were well balanced between treatment groups.5,6 In summary,
2,089 (44.2%) of 4,724 patients had node-positive disease, and
1,542 (32.6%) of 4,724 patients had received adjuvant chemo-
therapy. The mean age at random assignment was 64.2 years
(standard deviation, 8.2 years). At the time of the data snapshot
(September 4, 2013), the median follow-up in patients still
known to be alive was 120.0 months (interquartile range, 114.8 to
122.0 months; range, 2.9 to 164.1 months); the analysis was based
on more than 39,000 woman-years of follow-up. A total of 74.7%
of patients had at least 10 years of follow-up or had previously
died.
Efficacy
In the ER-positive/unknown population, 1,111 of 4,599
patients experienced a BCFS event (508 [22.1%] of 2,294 in the
exemestane group and 603 [26.2%] of 2,305 in the tamoxifen
group). A reduction in the risk of breast cancer–related events
was observed; the absolute difference at 10 years was 4.0%
(95% CI, 1.2% to 6.7%), and the hazard ratio (HR) was 0.81
(95% CI, 0.72 to 0.92) in favor of a switch to exemestane
(Fig 2A).
In the ER-positive/unknown population, 940 of 4,599 patients
died (445 [19.4%] of 2,294 in the exemestane group and 495
[21.5%] of 2,305 in the tamoxifen group). A modest improvement
in OS was seen with exemestane; the absolute survival difference at
10 years was 2.1% (95% CI,20.5% to 4.6%), and the HR was 0.89
(95% CI, 0.78 to 1.01), in favor of a switch to exemestane (Fig 2B).
The numerical difference in deaths was observed mainly in deaths
as a result of breast cancer, and rates of intercurrent deaths were
similar between randomly assigned treatment groups (Table 1).
Results were similar when the ITT population was considered, with
467 (19.9%) of 2,352 patients in the exemestane group dying, and
510 (21.5%) of 2,372 patients in the tamoxifen group dying (HR,
0.91; 95% CI, 0.80 to 1.03; Fig 2C).
In the ER-positive/unknown population, 659 of 4,599
patients reported a BCSS event (303 [13.2%] of 2,294 patients
in the exemestane group, and 356 [15.4%] of 2,305 patients
in the tamoxifen group). The absolute BCSS difference at 10
years was 2.3% (95% CI, 20.0% to 4.6%), and the HR was
0.84 (95% CI, 0.72 to 0.98) in favor of a switch to exemestane
(Fig 2D).
A total of 1,392 DFS events have been reported in only the
patients with ER-positive/unknown disease (650 [28.3%] of
2,294 in the exemestane group, and 742 [32.2%] of 2,305 in the
tamoxifen group). The highly signiﬁcant improvement in DFS
associated with a switch to exemestane that was noted pre-
viously remained, and no convergence of survival curves was
seen (Fig 2E). This sustained beneﬁt translated to an absolute
difference in the proportion who remained alive and disease
free at 10 years of 3.8% (95% CI, 0.9% to 6.6%). This dif-
ference remained in multivariable analyses that adjusted for
nodal status, prior HRT use, and prior chemotherapy; the HR
of 0.83 favored a switch to exemestane (95% CI, 0.75 to 0.93;
P = .001).
With competing risks methodology, in which all outcomes
were investigated in a single analysis, the cumulative incidence of
intercurrent deaths increased steadily throughout the follow-up
period and was comparable between randomly assigned treatment
groups (Fig 3). In consideration of breast cancer events (after
adjustment for competing risks), the early beneﬁt from a switch
to exemestane was maintained throughout follow-up (Gray’s test
P = .002).
No statistically signiﬁcant difference was seen between the
randomly assigned groups in the number of patients who reported
a new primary CLB (exemestane [n = 56] and tamoxifen [n = 75];
HR, 0.73; 95% CI, 0.52 to 1.03; Table 1), although the observed HR
was consistent with that of other trials that have explored the
additional preventive beneﬁts of aromatase inhibitors compared
with tamoxifen.17 Numerically, fewer nonbreast second primary
cancers were reported with exemestane (n = 143) than with ta-
moxifen (n = 191; Table 1). Analyses of incidence of distant re-
currence and nonbreast second primary cancer by age at random
assignment reﬂect data presented previously; there was a sugges-
tion that second primary cancer incidence increases with age, but
Randomly assigned (N = 4,740)
Unevaluable (n = 8) Unevaluable (n = 8)
ER-positive/unknown 
efficacy analysis
population
ER-positive or unknown
(n = 2,294)
ER-positive or unknown 
(n = 2,305)
ER-negative (n = 67)ER-negative (n = 58)
Evaluable patients (n = 4,724)
Randomly assigned to
tamoxifen (n = 2,372)
Randomly assigned to
exemestane (n = 2,352)
ITT efficacy analysis
population
Fig 1. CONSORT diagram. ER, estrogen
receptor; ITT, intention to treat.
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Fig 2. Survival results in study populations: estrogen receptor–positive/unknown (n = 4,599) and intention to treat (n = 4,724). (A) Breast cancer–free survival in the ER–positive/
unknown population. (B) Overall survival (OS) in the ER-positive/unknown population, and (C) in the intention-to-treat population. (D) Breast cancer–speciﬁc survival (BCSS) in the
ER-positive/unknown population. (E) Disease-free survival (DFS) in the ER-positive/unknown population. Exe, exemestane; HR, hazard ratio; Tam, tamoxifen.
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no association was observed between age and distant recurrence
incidence (trend test P = .08 and .22, respectively; Appendix Table
A1 and Fig A1, online only).
Results of TTDR analyses across the entire follow-up period
reﬂected other efﬁcacy end points. The absolute difference in the
rate of distant recurrence or breast cancer death at 10 years was
2.6% (95% CI, 0.2% to 5.1%), and the HR was 0.84 (95% CI, 0.74
to 0.96) in favor of a switch to exemestane. Analyses of TTDR after
completion of endocrine therapy—equivalent to approximately
5 years after diagnosis—included 4,147 patients known to be event
free at 2.5 years after random assignment (exemestane [n = 2,091]
and tamoxifen [n = 2,056]; Table 2). No statistically signiﬁcant
difference in TTDR during this period was observed between
randomly assigned treatment groups (HR, 0.94; 95% CI, 0.80 to
1.10; P = .41), which reﬂects the observation that the initial dif-
ference in disease outcome observed during the treatment period
was maintained throughout the follow-up period. After inclusion
in a multivariable Cox proportional hazards model, age at random
assignment, nodal status, hormone receptor status, previous HRT
use, and tumor size but not grade, had a signiﬁcant effect on the
risk of TTDR event after completion of endocrine therapy (ie, of
late relapse). Of note, risk of late distant recurrence in patients with
tumor sizes. 5 cm at diagnosis was almost double that of patients
with tumors, 2 cm (HR, 1.92; 95% CI, 1.28 to 1.90), and the risk
was more than six times greater in patients who had $10 nodes
involved than in patients who were node-negative at random
assignment (HR, 6.10; 95% CI, 4.41 to 8.44) after adjustment for
other factors.
Fractures
No statistically signiﬁcant difference was observed in the
proportion of patients who reported at least one fracture event in
the post-treatment period with 196 (9.3%) of 2,105 patients in the
Table 1. Efﬁcacy Events by Treatment Group in the ER-Positive/Unknown Population
Event
No. (%) of Events in
ER-Positive/Unknown Population
Exemestane
(n = 2,294)
Tamoxifen
(n = 2,305)
Total
(N = 4,599)
DFS ﬁrst event 650 (28.3) 742 (32.2) 1,392 (30.3)
Total BCFS events 508 603 1,111
Distant recurrence 369 420 789
Local recurrence 81 109 190
Second primary breast cancer 58 74 132
Intercurrent death 142 139 281
All deaths 445 (19.4) 495 (21.5) 940 (20.4)
Breast cancer 263 310 573
Unknown cause 40 46 86
Other known cause 142 139 281
Other cancer 40 60 100
Vascular 36 23 59
Cardiac 30 23 53
Other 36 33 69
Distant recurrence 403 (17.6) 469 (20.4) 872 (19.0)
To known site 346 393 739
Visceral only 129 130 259
Soft tissue/nodal only 29 25 54
Visceral and soft tissue/nodal 15 18 33
Total sites not including bone 173 173 346
Bone only 87 127 214
Visceral and bone 60 63 123
Visceral, bone, and soft tissue/nodal 15 18 33
Bone and soft tissue/nodal 11 12 23
Total sites including bone 173 220 393
Breast cancer death with no previous recurrence 17 28 45
Death as a result of unknown cause 40 48 88
Contralateral breast cancer 56 (2.4) 75 (3.3) 131 (2.8)
Nonbreast second primary cancer 143 (6.2) 191 (8.3) 334 (7.3)
Uterus 15 28 43
GI, upper 24 20 44
GI, lower 20 28 48
Lung 14 29 43
Melanoma 10 9 19
Ovary 10 8 18
Hematologic 15 17 32
Kidney 5 8 13
Other 30 44 74
NOTE. Events were those that contributed to end points of interest.
Abbreviations: BCFS, breast cancer–free survival; DFS, disease-free survival; ER, estrogen receptor.
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exemestane group and 163 (8.0%) of 2,036 patients in the ta-
moxifen group (P = .14).
DISCUSSION
This updated and ﬁnal analysis of IES demonstrates that the beneﬁt
associated with a switch to exemestane observed early in the
follow-up period remained undiminished by additional follow-up.
As the IES population aged, incidences of non–breast cancer deaths
and nonbreast second primary cancers have increased, which has
led to a dilution of OS results. However, a modest beneﬁt from the
switch to exemestane can still be seen, with an absolute difference
in OS at 10 years after random assignment of 1.6%. As suggested
previously, BCFS (which does not include non–breast cancer
deaths) remains the most appropriate measure of treatment efﬁ-
cacy in this setting; an absolute beneﬁt of 4.0% from the switch to
exemestane was observed at 10 years. Analyses that account for
competing events of intercurrent death and nonbreast second
primary cancer showed an absolute difference in breast cancer
event at 10 years of 3%.
The IES trial compared treatments for a duration of up to 5
years. Recent large, randomized controlled trials18-20 have dem-
onstrated an improvement in disease-related outcomes associated
with continuation of tamoxifen or aromatase inhibitor treatment
past the standard 5 years of treatment. However, long-term use of
endocrine therapy is associated with many adverse effects, some of
which substantially affect patient well-being, such as osteoporosis,
vasomotor problems, and musculoskeletal conditions.21 There
remains great clinical need to identify patients who remain
at high risk of disease relapse after completion of 5 years of
endocrine therapy who may beneﬁt from additional treatment
and, conversely, patients who may be spared this treatment
because of low residual risk.
Results of analyses partitioned at 2.5 years after random as-
signment support conclusions made previously that the difference
in disease-related outcome observed at 10 years between treatment
groups is due tomaintenance of the initial on-treatment divergence
between groups rather than any emerging post-treatment effect.
Multivariable analyses of clinical factors that affect the time to late
distant recurrence identiﬁed age at random assignment, nodal
involvement, hormone receptor status, previous HRT use, and
tumor size, although the relationship between HRT use and
late distant recurrence is confounded by geographic region.
The observation that tumor grade no longer retains prognostic
signiﬁcance in this setting after adjustment for other factors
reﬂects previous analyses of retrospective case series22 and com-
parable analyses of the ATAC trial.12 The authors of this analysis
also demonstrated the value of the PAM50-based risk of re-
currence score as an independent predictor of late distant re-
currence; other molecular scores studied (eg, IHC4, Oncotype
DX) did not add prognostic information when added to clinical
data.13
In summary, the IES and other contemporaneous studies have
established that a strategy of a switch to an aromatase inhibitor
after 2 to 3 years of tamoxifen can lead to sustained beneﬁts in
terms of reduction of disease recurrence and breast cancer mor-
tality. The identiﬁcation of patients who remain at higher risk of
disease recurrence after the completion of 5 years of endocrine
therapy (whether tamoxifen, an aromatase inhibitor, or a combi-
nation of the two) according to clinical factors, such as nodal
involvement and tumor size, will aid decision making about the
administration of additional endocrine therapy or additional
therapeutic agents.
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Fig A1. Distant recurrence and nonbreast second primary incidence by age.
Table A1. Distant Recurrence and Nonbreast Second Primary Incidence by Age
Age at Random
Assignment (years)
Distant Recurrence Nonbreast Second Primary
No. of Events Incidence Rate (per 1,000) 95% CI No. of Events Incidence Rate (per 1,000) 95% CI
, 55 88 20.1 16.3 to 24.8 25 5.5 3.7 to 8.2
55-59 172 21.7 18.7 to 25.1 68 8.4 6.6 to 10.6
60-64 154 17.4 14.9 to 20.4 83 9.3 7.5 to 11.5
65-69 149 20.2 17.2 to 23.7 69 9.2 7.3 to 11.7
$ 70 176 20.9 18.0 to 24.2 89 10.4 8.5 to 12.9
Total 739 20.0 18.6 to 21.5 334 8.9 8.0 to 9.9
Nonparametric test for trend P = .223 P = .079
© 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Morden et al
Downloaded from ascopubs.org by University of Leeds - Periodicals Department on August 24, 2017 from 129.011.023.117
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
